Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates The dataset was shared as part of a poster presentation at the American Diabetes Association’s (ADA) 86th Scientific Sessions BOULDER, Colo., June 5, 2026 /PRNewswire/ — Ambrosia Biosciences Inc….

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks